What is Sutro Biopharma's R&D?

Sutro Biopharma (STRO) reported R&D of $36.55M in Q1 2026.

How has Sutro Biopharma's R&D changed year-over-year?

Sutro Biopharma's R&D decreased by 29.2% year-over-year, from $51.6M to $36.55M.

What is the long-term trend for Sutro Biopharma's R&D?

Over 4 years (2021 to 2025), Sutro Biopharma's R&D has grown at a 12.4% compound annual growth rate (CAGR), from $104.4M to $166.42M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Sutro Biopharma STRO R&D

R&D at other companies

RegenxbioRGNX

$57.34M+8.0%

Nuvectis Pharma, Inc.NVCT

$4.11M+11.6%

XencorXNCR

$64.67M+10.4%

AnaptysBio, Inc.ANAB

$33.99M-17.5%

SchrodingerSDGR

$43.82M-4.4%

CytomX TherapeuticsCTMX

$19.24M+2.0%

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's R&D?: Sutro Biopharma (STRO) reported R&D of $36.55M in Q1 2026.
How has Sutro Biopharma's R&D changed year-over-year?: Sutro Biopharma's R&D decreased by 29.2% year-over-year, from $51.6M to $36.55M.
What is the long-term trend for Sutro Biopharma's R&D?: Over 4 years (2021 to 2025), Sutro Biopharma's R&D has grown at a 12.4% compound annual growth rate (CAGR), from $104.4M to $166.42M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.